Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Evolus, Inc. (EOLS : NSDQ)
 
 • Company Description   
Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California.

Number of Employees: 167

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.18 Daily Weekly Monthly
20 Day Moving Average: 546,365 shares
Shares Outstanding: 56.05 (millions)
Market Capitalization: $738.73 (millions)
Beta: 2.07
52 Week High: $14.30
52 Week Low: $5.06
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 16.84% 27.55%
12 Week 50.97% 63.17%
Year To Date 102.46% 139.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
520 Newport Center Dr. Suite 1200
-
Newport Beach,CA 92660
USA
ph: 949-284-4555
fax: -
ir@evolus.com http://www.evolus.com
 
 • General Corporate Information   
Officers
David Moatazedi - President and Chief Executive Officer
Vikram Malik - Chairman
Lauren P. Silvernail - Chief Financial Officer and Executive Vice Preside
Simone Blank - Director
Robert Hayman - Director

Peer Information
Evolus, Inc. (BJCT)
Evolus, Inc. (CADMQ)
Evolus, Inc. (APNO)
Evolus, Inc. (UPDC)
Evolus, Inc. (IMTIQ)
Evolus, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 30052C107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 56.05
Most Recent Split Date: (:1)
Beta: 2.07
Market Capitalization: $738.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.26 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 10.98
Price/Cash Flow: -
Price / Sales: 6.09
EPS Growth
vs. Year Ago Period: -293.75%
vs. Previous Quarter: 6.06%
Sales Growth
vs. Year Ago Period: 177.00%
vs. Previous Quarter: -2.16%
ROE
03/31/22 - -80.20
12/31/21 - -60.65
09/30/21 - -145.33
ROA
03/31/22 - -30.31
12/31/21 - -21.53
09/30/21 - -27.23
Current Ratio
03/31/22 - 3.51
12/31/21 - 3.10
09/30/21 - 1.94
Quick Ratio
03/31/22 - 3.42
12/31/21 - 3.07
09/30/21 - 1.89
Operating Margin
03/31/22 - -58.28
12/31/21 - -46.96
09/30/21 - -65.32
Net Margin
03/31/22 - -58.28
12/31/21 - -46.96
09/30/21 - -162.78
Pre-Tax Margin
03/31/22 - -58.25
12/31/21 - -46.92
09/30/21 - -162.95
Book Value
03/31/22 - 1.20
12/31/21 - 1.47
09/30/21 - 1.75
Inventory Turnover
03/31/22 - 16.55
12/31/21 - 14.90
09/30/21 - 10.53
Debt-to-Equity
03/31/22 - 1.06
12/31/21 - 0.87
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 51.49
12/31/21 - 46.52
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©